From: Etiology and management of hypertension in patients with cancer
| VEGF inhibitors | TKI | Proteosome inhibitors | Alkylating agents | Miscellaneous |
|---|---|---|---|---|
| Bevacizumab | Sorafenib | Bortezomib | Cyclophosphamide | Steroids |
| Ramucirumab | Sunitinib | Carfilzomib | Ifosfamide | Abiraterone |
| Aflibercept | Lenvatinib | Ixazomib | Busulfan | Recombinant human erythropoietin |
| Axitinib | Cisplatin | Cyclosporin | ||
| Ibrutinib | Tacrolimus | |||
| Cabozantinib | Paclitaxel | |||
| Pazopanib | Copanlisib | |||
| Nintedanib | Daratumumab | |||
| Regorafinib | Elotuzumab |